The Ozempic Generation: What the Interventional Radiologist Needs to Know About <scp>GLP</scp> ‐1 Agonists

Glucagon-like peptide 1 receptor (GLP-1) agonists have been traditionally used in the treatment of type II diabetes. However, in recent times they have become a cornerstone in the pharmacological management of weight loss, and their use is increasing rapidly. Interventional Radiologists (IRs) need to understand GLP-1 agonists as they will increasingly encounter patients taking these medications in their daily practice, with implications for quality of care. These drugs have the potential to impact fasting glucose levels and gastric emptying, with implications for peri-procedural management when giving conscious sedation for an IR procedure. There is a need for IRs to adapt to the modern landscape. This review discusses the pharmacological effects, peri-procedural implications, and the need for IR-specific guidance in managing patients taking GLP-1 agonists.